1. Pink Sheet

FTC Seeks Input On How PBM Rebating Practices Affect Drug ‘Affordability,’ Access

 
• By Cathy Kelly

With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.

Last In-Depth FTC Study On PBMs Was 2005 • Source: Alamy

The Federal Trade Commission is requesting public comment on a wide range of pharmacy benefit manager business activities including contract terms, rebates, fees, pricing policies, steering methods, conflicts of interest, and consolidation and how those practices impact patients, physicians, employers, and independent and chain pharmacies.

The request for information “will enable agency staff to study a wide array of PBM business practices and issues and will help inform the agency’s policy and enforcement work,” explains...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.